Participated · Series B · Aug 2026

QuantHealth offers an AI-driven clinical trial simulation platform that enables life sciences companies to evaluate, optimize, and de-risk clinical and commercial decisions before enrolling patients or committing capital. The company serves pharmaceutical and biotechnology organizations and is led by CEO Orr Inbar. QuantHealth is based in Tel Aviv, Israel. Following its Series B, the company plans to scale enterprise-wide impact, accelerate adoption of simulation-first clinical development, advance R&D capabilities, grow its workforce, and expand its product portfolio. The article does not disclose revenues, user counts, or prior funding rounds.

Participated · Series A · Feb 2026

Flinn.ai is a Vienna-based software startup focused on streamlining regulatory and quality management for MedTech companies through artificial intelligence. Its cloud platform automates tasks such as post-market surveillance, literature evaluation, incident reporting, and compliance with European MDR/IVDR standards, enabling faster and more efficient product lifecycles. Current enterprise customers include industry leaders Carl Zeiss, Philips, and Paul Hartmann, underscoring early market adoption among large manufacturers. By reducing manual effort in compliance activities, the software targets quicker market access and lower operational costs for its users. The company plans to direct newly raised capital toward scaling operations and accelerating product development. No revenue or user numbers were disclosed, but the presence of notable clients indicates early commercial traction.

Participated · Series A · Feb 2026

Take2 is an AI agents platform focused on streamlining healthcare recruiting. Its flagship product, the AI Interviewer, autonomously conducts phone interviews around the clock, evaluates candidates, records calls, and syncs results directly into applicant tracking systems without human intervention. Trained on healthcare-specific hiring data, the system delivers predictive insights that improve quality of hire and employee retention while addressing high vacancy costs and turnover in the sector. The company already serves several of the largest U.S. health systems and reports growing adoption as organizations seek faster, more scalable staffing solutions. With new capital, Take2 intends to launch additional agents that handle sourcing, screening, credential verification, scheduling, and onboarding, moving toward fully automating the end-to-end hiring funnel. Management believes the platform can save healthcare providers millions of dollars each year by reducing manual workload and improving retention. The firm has just secured a $14 million Series A to accelerate these plans.

Participated · Equity · Oct 2025

Andel is building a cooperative pharmacy-benefit platform that pools the buying power of employer members to buy GLP-1 weight-loss medications and other costly branded drugs directly from manufacturers at below-market rates. Employers choose a subsidy level, and Andel handles prescription verification, payment, and next-day delivery through its native applications and wholly owned Andel Pharmacy, LLC. By bypassing traditional pharmacy-benefit managers, the model aims to lower costs for employers while giving employees immediate access to brand-name medicines without prior-authorization hurdles. Co-founders Jay Bregman—whose prior ventures include Hailo and Thimble—and pharmacist Ritu Malhotra, PharmD, combine startup and healthcare-benefits expertise to navigate the complex drug-pricing ecosystem. The company announced plans to launch nationwide in early 2026. Andel has raised $4.5 million to fund this rollout, but it has not yet disclosed revenue, user, or prescription-volume metrics.

Participated · Equity · Oct 2025

Onos Health develops proprietary artificial-intelligence models trained on extensive behavioral-health data to help insurers make real-time clinical decisions and eliminate manual processes such as prior authorization. Its platform analyzes payer information to map ideal care pathways across entire member populations, aiming to maximize clinical outcomes and minimize unnecessary spend. Early deployments have produced 60%+ faster care decisions, a 30%+ rise in provider adherence to evidence-based standards, and a 55% boost in provider network satisfaction. The company collaborates closely with an advisory board that includes former executives from Optum Behavioral Health, Kaiser, and Oscar Health. Onos plans to use newly secured capital to meet demand from several large U.S. health plans and to expand its clinical and data-science teams. Financially, the company has just closed an oversubscribed $6.3 million venture round, adding to its earlier pre-seed backing. No revenue or user figures were disclosed, but the company positions itself as redirecting billions in misallocated behavioral-health spend toward high-quality care.